Literature DB >> 8625213

The National Cancer Data Base report on ovarian cancer. American College of Surgeons Commission on Cancer and the American Cancer Society.

H E Averette1, M F Janicek, H R Menck.   

Abstract

BACKGROUND: Reports generated from the National Cancer Data Base (NCDB), a joint project of the American College of Surgeons Commission of Cancer and the American Cancer Society, have described trends in demographics, stage, treatment patterns, and survival for a variety of cancers. In this report, the most current (1991) data for ovarian cancer are presented and include some comparisons with 1985/1986 data.
METHODS: Three calls for data from hospital registries across the United States have yielded 17,114 ovarian cancer cases for 1985, 1986, and 1991 combined. These data represent approximately 23%, 23%, and 43%, respectively, of the annual number of cases of ovarian cancer in the United States for those years.
RESULTS: One-fourth of the reported cases of ovarian cancer were diagnosed in women less than 50 years of age. Younger patients (< 40 years) were more likely to have received conservative therapy (unilateral oophorectomy), consistent with their high prevalence (59%) of Stage I disease. The number of patients reported with an unknown American Joint Committee on Cancer (AJCC) stage decreased from 49% in 1985/1986 to 17% in 1991, although the distribution within stages was unchanged. Increases in important staging procedures were reported in 1991, with threefold increase in the proportion of debulking procedures and a 50% increase in omentectomies accompanying hysterectomy compared with 1985/1986. More advanced disease was reported for those of older age, lower income, African Americans, and patients in smaller hospitals. Relative 5-year survival rates were 74% for patients with Stage I disease, 58% for Stage II, 30% for Stage III, and 19% for Stage IV. Asians and Hispanics presented with a relatively high rate of Stage I-II disease (45%) compared with non-Hispanic whites and African Americans (38% and 33%, respectively). Hispanics presented with the most favorable Stage I/IV ratio (1.5) and had an overall 5-year survival of 50% compared with 41% and 37% for non-Hispanic whites and African Americans (Stage I/IV ratios of 1.0 and 0.7, respectively). There was little difference reported in the use of multimodality treatment between 1985/1986 and 1991.
CONCLUSIONS: A trend toward more complete surgery with full surgical/pathologic staging was observed in 1991, but there was not yet evidence to indicate significant improvements in ovarian cancer survival compared with published figures during the past 10-15 years. Important ethnic and demographic differences in type of surgery and survival were noted but could not be differentiated from differences in tumor stage.

Entities:  

Mesh:

Year:  1995        PMID: 8625213     DOI: 10.1002/1097-0142(19950915)76:6<1096::aid-cncr2820760626>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.

Authors:  Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

2.  Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer.

Authors:  Digant Gupta; Carolyn A Lammersfeld; Pankaj G Vashi; Donald P Braun
Journal:  J Ovarian Res       Date:  2010-10-12       Impact factor: 4.234

3.  Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells.

Authors:  Wei Xiang; Pauline Wimberger; Torsten Dreier; Joachim Diebold; Doris Mayr; Patrick A Baeuerle; Rainer Kimmig
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-18       Impact factor: 4.553

4.  Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer.

Authors:  Xianglin L Du; Rohan C Parikh; David R Lairson; Sharon H Giordano; Putao Cen
Journal:  Med Oncol       Date:  2013-01-10       Impact factor: 3.064

5.  Accuracy of 64-multidetector computed tomography in diagnosis of adnexal tumors.

Authors:  Fatemeh Gatreh-Samani; Mohammad Kazem Tarzamni; Elaheh Olad-Sahebmadarek; Ali Dastranj; Aimaz Afrough
Journal:  J Ovarian Res       Date:  2011-08-17       Impact factor: 4.234

6.  Ovarian cancer in younger vs older women: a population-based analysis.

Authors:  J K Chan; R Urban; M K Cheung; K Osann; J Y Shin; A Husain; N N Teng; D S Kapp; J S Berek; G S Leiserowitz
Journal:  Br J Cancer       Date:  2006-10-31       Impact factor: 7.640

7.  CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer.

Authors:  C Peters-Engl; A Obermair; H Heinzl; P Buxbaum; P Sevelda; M Medl
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

8.  Regulatory T lymphocytes and transforming growth factor beta in epithelial ovarian tumors-prognostic significance.

Authors:  Izabela Winkler; Barbara Wilczynska; Agnieszka Bojarska-Junak; Marek Gogacz; Aneta Adamiak; Krzysztof Postawski; Dorota Darmochwal-Kolarz; Tomasz Rechberger; Jacek Tabarkiewicz
Journal:  J Ovarian Res       Date:  2015-06-17       Impact factor: 4.234

9.  Expression of RET finger protein predicts chemoresistance in epithelial ovarian cancer.

Authors:  Maiko Horio; Takuya Kato; Shinji Mii; Atsushi Enomoto; Masato Asai; Naoya Asai; Yoshiki Murakumo; Kiyosumi Shibata; Fumitaka Kikkawa; Masahide Takahashi
Journal:  Cancer Med       Date:  2012-09-13       Impact factor: 4.452

10.  The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?

Authors:  Jk Chan; K Fuh; Jy Shin; Mk Cheung; Cb Powell; L-m Chen; Ds Kapp; K Osann
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.